HOME >> BIOLOGY >> NEWS
High BMI doesn't always spell obesity, Jackson Laboratory researchers show

For years doctors have used the body mass index (BMI), a ratio of height and weight, to characterize the clinical weight status of their patients. The lower the number, the presumption goes, the leaner the person, and anyone with a BMI above 30 is characterized as obese and at high risk for the associated complications.

But the BMI has come under scrutiny lately, and other techniques that measure how the weight is distributed on the body are thought to provide a better way to assess risk. Now a study in mice by scientists at The Jackson Laboratory indicates that the usefulness of the BMI is suspect even at the genetic level.

In research published in PLoS Genetics, the investigators from Jackson and the J.L. Pettis VA Medical Center and led by Dr. Gary Churchill of Jackson used a combination of computational, molecular and genetic tools to identify locations on the mouse genome that influence adiposity (amount of body fat), overall body size and bone structure. Applying an analytical technique called "structural equation modeling" to the genetic and physical characteristics of mouse inbred crosses, the scientists went beyond the one-gene, one-trait approach to reveal the networks of effects created by the influence of multiple genes.

"We found that the genetic network affecting adiposity is separate from that affecting overall body size," Churchill says, "providing strong evidence that a high weight is not necessarily directly associated with a high percentage of fat."

At the clinical level, the research suggests that more refined measurements are needed to distinguish individuals with a large body mass from those who are truly obese and consequently at high risk for diabetes, heart disease and other disorders.

Churchill and colleagues at Jackson recently received a 5-year, $15.1 million National Institute of General Medical Sciences grant to form an interdisciplinary Center for Genome Dynamics to study compl
'"/>

Contact: Joyce Peterson
joyce.peterson@jax.org
207-288-6058
Jackson Laboratory
20-Jul-2006


Page: 1 2

Related biology news :

1. Heart intervention doesnt outweigh medicine in study
2. This party doesnt start until the hosts arrive
3. Failed experiment yields a biocontrol agent that doesnt trigger antibiotic resistance
4. Acetaminophen safe to use after heart attack but doesnt protect the heart
5. In stretching, pain doesnt equal gain; but if NO isnt producing, stretching wont help
6. Study finds evolution doesnt always favor bigger animals
7. If oxytocin eating role doesnt mature at birth, what other situations affect its impact?
8. Size doesnt matter
9. To sea or not to sea: When it comes to salmon sex, size sometimes doesnt matter
10. What the eye doesnt see
11. Exercise doesnt work for us all

Post Your Comments:
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) ... report "Neuroprotection - Drugs, Markets and Companies" ... describes the role of neuroprotection in acute disorders ... system as well as in chronic diseases such ... mechanisms of damage to neural tissues are similar ...
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... attending the World Pork Expo, June 3-5 in ... this year in a Wall Street Journal article ...
(Date:5/28/2015)... MIAMI BEACH, Fla. , May 28, 2015 /PRNewswire/ ... data supporting the anti-cancer potential of its growth hormone-releasing ... presentation at the 2015 ASCO Annual Meeting. The ... the target for Biscayne,s anti-cancer GHRH blockers, is present ... receptor status. These findings suggest that GHRH antagonists could ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
Cached News: